2024
State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care.
Balmaceda N, Petrillo A, Krishnan M, Zhao J, Kim S, Klute K, Sundar R. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. American Society Of Clinical Oncology Educational Book 2024, 44: e431060. PMID: 38771996, DOI: 10.1200/edbk_431060.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCombined Modality TherapyEsophageal NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyMolecular Targeted TherapyPrecision MedicineStomach NeoplasmsConceptsGastroesophageal cancerIntegration of immune checkpoint inhibitorsChimeric antigen receptor T cellsImmune checkpoint inhibitorsMetastatic gastroesophageal cancerPD-1 inhibitorsAdoptive cell therapyImmunotherapy-based approachesResectable gastroesophageal cancerAntibody-drug conjugatesCheckpoint inhibitorsPD-1Perioperative chemotherapyTargeted therapyT cellsTreatment paradigmFGFR2 inhibitorsCell therapyClinical challengeBispecific antibodiesImprove outcomesCancer treatmentReduced toxicityTherapyInhibitors
2018
A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials
Garces A, Ang J, Ameratunga M, Chénard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U. A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. European Journal Of Cancer 2018, 104: 32-38. PMID: 30316017, PMCID: PMC6259582, DOI: 10.1016/j.ejca.2018.08.019.Peer-Reviewed Original ResearchConceptsPhase I clinical trialElectrolyte abnormalitiesBaseline hypoalbuminaemiaOverall survivalClinical significanceDose-limiting toxicity windowPrognostic factors of OSOncology phase I trialsInferior median OSFactors of OSPhase I patientsPhase I trialRetrospective chart reviewSerum albumin levelAssociated with hypomagnesaemiaRoyal Marsden HospitalCox regression analysisPhase I populationDrug Development UnitMedian OSPrognostic factorsPrognostic significanceI patientsI trialAlbumin levels
2017
Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies
Sundar R, Hong D, Kopetz S, Yap T. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discovery 2017, 7: 558-560. PMID: 28576843, PMCID: PMC5458523, DOI: 10.1158/2159-8290.cd-17-0087.Commentaries, Editorials and LettersMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsHumansMitogen-Activated Protein KinasesMolecular Targeted TherapyMutationProto-Oncogene Proteins B-rafAdvances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
Dolly S, Collins D, Sundar R, Popat S, Yap T. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs 2017, 77: 813-827. PMID: 28378229, DOI: 10.1007/s40265-017-0732-2.Peer-Reviewed Educational MaterialsMeSH KeywordsAntineoplastic AgentsBiomarkers, TumorCarcinoma, Non-Small-Cell LungDrug DiscoveryDrug Resistance, NeoplasmHumansLung NeoplasmsMolecular Targeted TherapyConceptsAnaplastic lymphoma kinaseEpidermal growth factor receptorDevelopment of molecular-targeted agentsAdvent of immune checkpoint inhibitorsNon-small-cell lung cancerPredictive biomarkers of responseEmergence of acquired resistanceTreatment approachesAdvanced NSCLC patientsImmune checkpoint inhibitorsProgression-free survivalMolecular targeted agentsBiomarkers of responseNon-small-cellTreatment of patientsCancer-related mortalityGrowth factor receptorMutation-specific inhibitorsAnti-tumor agentsCheckpoint inhibitorsNSCLC patientsGene aberrationsDownstream signaling blockadePredictive biomarkersMolecular subtypesCombining Molecularly Targeted Agents: Is More Always Better?
Sundar R, Valeri N, Harrington K, Yap T. Combining Molecularly Targeted Agents: Is More Always Better? Clinical Cancer Research 2017, 23: 1123-1125. PMID: 27836864, DOI: 10.1158/1078-0432.ccr-16-2399.Commentaries, Editorials and Letters